Abstract: Novel tetracyclic spirobenzazepine compounds of the formula ##STR1## or a pharmaceutically-acceptable salt, amide or ester thereof, which are dopamine D-1 receptor antagonists useful for treating dopamine-related neurological and psychological disorders, cognitive impairment, attention deficit disorders and addictive behavior disorders.

Abstract: Novel compounds of Formula (I): ##STR1## or pharmaceutically acceptable salts, esters and amides thereof, wherein A is O, C, CH or CH.sub.2, n is 0 or 1, and the dotted line is a single bond when A is O or CH.sub.2 and a double bond when A is CH or when n=0, A is C andR.sub.6 and A taken together form a nitrogen-containing heterocycle;R is hydrogen, lower alkyl or a readily cleavable group;R.sub.1 is selected from hydrogen, halogen, lower alkyl, haloalkyl and lower alkoxy;R.sub.2 is selected from hydrogen, halogen, lower alkyl and haloalkyl or, taken together with R.sub.8, forms a fused ring;R.sub.3 is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl or arylalkyl or, taken together with R.sub.4, forms a spirocycloalkyl or, taken together with R.sub.5, forms a fused cycloalkyl;R.sub.4 is hydrogen or alkyl or, taken together with R.sub.3, forms a spirocycloalkyl;R.sub.5 is hydrogen or alkyl or, taken together with R.sub.3, forms a fused cycloalkyl;R.sub.

Abstract: Novel compounds which are selective dopamine agonists are useful for treating disorders characterized by abnormal dopamine levels, such as Parkinson's Disease, as well as cardiovascular disorders.

Abstract: The present invention discloses a method of detecting melanin containing matter comprising reacting melanin containing matter with an enantiomer of 2, 3, 4, 5-tetrahydro-3-methyl-5 phenyl-1H-3-benzazepin-7-ol and determining the binding of said enantiomer with melanin. The invention also describes a method of delivering cytotoxic level of gamma radiation to pigmented melanoma comprising administering to a body carrying pigmented melanoma a cytotoxically effective radiation dosage of .sup.125 I-enantiomer of 2, 3, 4, 5-tetrahydro-3-methyl-5-phenyl-1H-3-benzazepin-7-ol having specific binding affinity for said melanoma. Other applications of the invention have also been described.